Polymorphic form XVI of fexofenadine hydrochloride
AssigneeTeva Pharmaceutical Industries Ltd.
InventorsBarnaba Krochmal, Dov Diller, Ben-Zion Dolitzky, Judith Aronhime, Shlomit Wizel, Boaz Gome, Igor Lifshitz
Life of this patent
Estimating the term…
Abstract
Provided is a crystalline (polymorphic) form of fexofenadine hydrochloride, denominated fexofenadine hydrochloride Form XVI.
Claims18
1-9. (canceled)
A pharmaceutical formulation comprising an effective amount of crystalline fexofenadine hydrochloride hydrate having a PXRD pattern with peaks at 10.1, 15.2, 18.6, 19.2, 20.1±0.2 degrees two theta, and a pharmaceutically acceptable excipient.
13-50. (canceled)
(canceled)
A method for preparing a pharmaceutical formulation comprising combining crystalline fexofenadine hydrochloride hydrate having a PXRD pattern with peaks at 10.1, 15.2, 18.6, 19.2, 20.1±0.2 degrees two theta with a pharmaceutically acceptable excipient.
Dependencies are inferred from the claim text.